Today, Regulus Therapeutics Inc. (RGLS) Short Interest Down 28.7% in November

Today, Regulus Therapeutics Inc. (RGLS) Short Interest Down 28.7% in November

Regulus Therapeutics Inc. (NASDAQ:RGLS) saw a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 3,066,842 shares, a drop of 28.7% from the October 31st total of 4,299,612 shares. Based on an average trading volume of 533,357 shares, the days-to-cover ratio is currently 5.8 days. Approximately 8.6% of the shares of the company are sold short.

A number of institutional investors have recently made changes to their positions in the company. Alps Advisors Inc. increased its position in shares of Regulus Therapeutics by 25.1% in the second quarter. Alps Advisors Inc. now owns 74,146 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 14,873 shares during the period. Bank of New York Mellon Corp increased its position in shares of Regulus Therapeutics by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 141,216 shares of the biopharmaceutical company’s stock worth $408,000 after buying an additional 20,118 shares during the period. California State Teachers Retirement System increased its position in shares of Regulus Therapeutics by 35.8% in the second quarter. California State Teachers Retirement System now owns 81,343 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 21,453 shares during the period. Bourgeon Capital Management LLC increased its position in shares of Regulus Therapeutics by 56.1% in the second quarter. Bourgeon Capital Management LLC now owns 70,704 shares of the biopharmaceutical company’s stock worth $204,000 after buying an additional 25,404 shares during the period. Finally, Wedbush Securities Inc. increased its position in shares of Regulus Therapeutics by 43.4% in the second quarter. Wedbush Securities Inc. now owns 47,061 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 14,246 shares during the period. 49.95% of the stock is currently owned by hedge funds and other institutional investors.

Regulus Therapeutics (NASDAQ:RGLS) opened at 2.55 on Tuesday. The company’s 50 day moving average price is $2.78 and its 200 day moving average price is $3.73. Regulus Therapeutics has a 52-week low of $2.12 and a 52-week high of $10.25. The company’s market cap is $134.95 million.

A number of brokerages have commented on RGLS. Needham & Company LLC reduced their price objective on Regulus Therapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, November 2nd. Wedbush reiterated an “outperform” rating and issued a $15.00 price objective (up previously from $13.00) on shares of Regulus Therapeutics in a research report on Wednesday, November 2nd. Finally, Cowen and Company downgraded Regulus Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 2nd. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $9.80.

About Regulus Therapeutics

Related posts

Leave a Comment